Mechanistically, EP has been shown to mitigate the pro‐inflammatory activity of HMGB1 in NASH, suppressing the activation of MAPK (p38, ERK, JNK), NF‐κB‐p65 and JAK1/STAT3 signalling pathways and protecting the diabetic liver from injury. The gene discussed is HMGB1; the disease is metabolic dysfunction-associated steatohepatitis.